The Healius Ltd (ASX: HLS) share price was in focus today after the company delivered a 2.2% increase in revenue to $1,373.2 million for FY26, with underlying net loss shrinking by 46.8% to $13.2 million.
What did Healius Limited report?
- Revenue from continuing operations rose 2.2% to $1,373.2 million (FY25: $1,344.2 million)
- Underlying EBITDA grew 8.1% to $258.6 million
- Underlying EBIT jumped 76.6% to $30.2 million
- Underlying loss after tax improved to $13.2 million from $24.8 million a year ago
- Reported loss after tax widened to $415.6 million, from $151.2 million, due chiefly to a $332 million non-cash goodwill impairment
- No dividend declared for FY26 (FY25: 41.3 cps special dividend)
What else do investors need to know?
Healius delivered operational improvements despite headwinds in the healthcare sector, including increased labour costs and limited Medicare indexation. Cost management helped contain annual spend, aided by a detailed workforce optimisation program reducing headcount by around 5%.
The Agilex Biolabs division performed strongly, growing revenue by 14.1% and EBITDA by over 67%. The company is reviewing strategic options for Agilex Biolabs, and an update for shareholders is expected ahead of the AGM.
Healius completed the major phase of its digital transformation program, with most collection centres now processing over 80% of episodes digitally. AI‑driven initiatives are delivering productivity gains and will continue to be rolled out across back-office and laboratory operations.
What’s next for Healius Ltd?
Looking ahead, Healius is focused on expanding higher margin revenue streams in diagnostics, capturing benefits from its completed digital platform rollouts, and further lifting network productivity. The group expects full-year labour cost pressures from regulatory changes, but remains confident about healthcare demand trends over the medium to long term.
The company maintains a strong balance sheet, ending FY26 with net debt of $32.8 million and well within its banking covenants. Management continues to target improved cashflow and margin restoration in FY27.
Healius Ltd share price snapshot
The Healius share price has been sold off over the past 12 months and is down 45%. This compares to a modest 2% gain by the S&P/ASX 200 index (ASX: XJO).
